These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 28084827)
1. Reply: Can Bisphosphonates Prevent Vitamin K Antagonist Toxicity in Patients with Idiopathic Pulmonary Fibrosis? Raghu G; Rochwerg B Am J Respir Crit Care Med; 2017 Jan; 195(2):271. PubMed ID: 28084827 [No Abstract] [Full Text] [Related]
2. Can Bisphosphonates Prevent Vitamin K Antagonist Toxicity in Patients with Idiopathic Pulmonary Fibrosis? Janssen R Am J Respir Crit Care Med; 2017 Jan; 195(2):269-270. PubMed ID: 28084819 [No Abstract] [Full Text] [Related]
3. Reply: Is a Trial of Vitamin K Antagonists and Bisphosphonates Possible in IPF? Margaritopoulos GA; Antoniou KM Am J Respir Crit Care Med; 2017 Jan; 195(2):271-272. PubMed ID: 28084829 [No Abstract] [Full Text] [Related]
4. Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns. Kawano-Dourado L; Zampieri F; Cavalcanti AB; Damiani LP; Kairalla RA Eur Respir J; 2016 Nov; 48(5):1523-1524. PubMed ID: 27799398 [No Abstract] [Full Text] [Related]
5. Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns. Kreuter M; Wijsenbeek MS; Vasakova M; Spagnolo P; Kolb M; Costabel U; Weycker D; Kirchgaessler KU; Maher TM Eur Respir J; 2016 Nov; 48(5):1524-1526. PubMed ID: 27799399 [No Abstract] [Full Text] [Related]
7. Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension. Henkens IR; Hazenoot T; Boonstra A; Huisman MV; Vonk-Noordegraaf A Eur Respir J; 2013 Apr; 41(4):872-8. PubMed ID: 22936704 [TBL] [Abstract][Full Text] [Related]
8. Reply: The New Idiopathic Pulmonary Fibrosis Acute Exacerbations Document: One Step Ahead but Still Suspended in the Air. Ryerson CJ; Corte TJ; Martinez FJ; Collard HR Am J Respir Crit Care Med; 2017 Jan; 195(2):269. PubMed ID: 28084823 [No Abstract] [Full Text] [Related]
10. N-acetylcysteine for idiopathic pulmonary fibrosis: the door is still open-Authors' reply. Behr J; Crestani B; Wells A; Kirchgaessler K; Albera C Lancet Respir Med; 2017 Jan; 5(1):e3. PubMed ID: 28000597 [No Abstract] [Full Text] [Related]
11. Reply to Horita and Takeshi: Thrombomodulin Did Not Benefit Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a Trial. Kondoh Y; Azuma A; Tagawa J; Homma S Am J Respir Crit Care Med; 2020 Jul; 202(1):151-152. PubMed ID: 32228231 [No Abstract] [Full Text] [Related]
12. Reply: Heparin versus Warfarin in Interstitial Pulmonary Fibrosis: The Quest for the Right Anticoagulant Continues. Margaritopoulos GA; Antoniou KM Am J Respir Crit Care Med; 2017 Jan; 195(1):142-143. PubMed ID: 28035862 [No Abstract] [Full Text] [Related]
13. Study the past to divine the future. Confucius' wisdom doesn't work for idiopathic pulmonary fibrosis. Kolb M; Jenkins G; Richeldi L Thorax; 2016 May; 71(5):399-400. PubMed ID: 27068097 [No Abstract] [Full Text] [Related]
14. [Idiopathic pulmonary fibrosis or atypical tuberculosis]. PANA C; SPINA G; PERELLI A Ann Ist Carlo Forlanini; 1955; 15(3):247-65. PubMed ID: 13302974 [No Abstract] [Full Text] [Related]
15. [Considerations on the radiological aspects of idiopathic pulmonary fibrosis & of tuberculous fibrotic manifestations]. MARTINOTTI G; MOTTA R Minerva Med; 1959 May; 50(39):1517-27. PubMed ID: 13666583 [No Abstract] [Full Text] [Related]
16. Predicting the future of patients with idiopathic pulmonary fibrosis: another step forward. Luppi F Lancet Respir Med; 2017 Dec; 5(12):911-913. PubMed ID: 29150408 [No Abstract] [Full Text] [Related]